Novo Nordisk A/S (ADR) (NYSE:NVO)

It is riding the global wave of rising affluence with the associated increase in diabetes.

12/13

Diabetes products - this is where it's at. Look at the stats and predictions for the disease in the coming years!

Good potential to make somebody some money.

produces most used dibetes drug, and has a grant to develop alzheimers treatment.

best in treating diabetes in world

Soon to be blockbuster diabetes drug. Possibility this same drug could be used to treat alzheimer's. The two biggest maladies facing the western world treated by one companies patented drug.

carstensen= smart guy

Alzhiemer's trials with a diabetes drug?

Victoza

Maybe a great company, but valution is too high.

Victoza...any questions?

Strong company, great products, lots of potential since healthcare will make great strides in the coming decades.

Steady income from insulin drug. Competition is not gaining any traction and diabetes is on the rise worldwide.

Expensive, but a great and growing company.

General thumbs up to Scandinavia.
Why?
A) Tops in Social Mobility
B) Tops in equitable wealth distribution
C) Tops in primary/secondary education
D) Exporters (hight tech end products, raw materials like plywood and oil, and industrial supply) who should do better as the rest of the world does.

Since this is a game about beating a general market, I figure it makes sense to say another general market will beat it.
So, I took all the stocks in Denmark, Finland, Norway and Sweden (sorry Iceland, next time don't let your bankers run amok) that are available to Fools, and thumbs-upped them (well, except for those I'd thumbed up already.)

StockScouter:9, Navellier:B, div >1%

They are a all around great company. Good to work for. Clear leader in diabetes research. Surging sales. The growth rate is up there with your Apples and Salesforces of the world. It is a little pricey, but worth it for a market leader, and well-run company.

In picking this stock it had to meet five conditions:
1. A clear leader in an industry with high barriers to competition.
2. Well managed and efficient: with a high ROIC and profit margin.
3. Strong balance sheet, free cash flow adequate to fund its dividend, and well managed debt.
4. A history of substantial dividends and dividend growth.
5. Has performed well in the current macroeconomic environment (i.e. inflation, loose monetary policy, rapid BRIC growth, dollar/euro weakness) by equaling or beating the return on gold (20%+ annually) over the last few years.

Not many companies can make that last claim! This one does.

NVO is the world leader in Diabetes care.